Vimta Labs Limited — PPTs, 03-11-2025: Investor Presentation

Vimta Labs reported a strong H1 FY26 with total income up 26.6% YoY to ₹203.8 Cr and PAT up 25.5% YoY to ₹38.8 Cr. Q2 FY26 saw total income at ₹104.5 Cr (up 17.1% YoY) and PAT at ₹19.9 Cr (up 17.1% YoY), with an EPS of ₹4.5. The company maintains healthy margins with Q2 EBITDA at 35.3% and PAT at 19.1%.

Vimta holds top positions in India for Pharma Analytical and Food Testing, also making significant overseas revenue contributions (36% from Pharma Analytical, 75% from Clinical Research). Growth is driven by capacity expansions, service innovations, new market penetration, and increasing demand for safe products across its diverse testing segments.

Key strategies include operational excellence, talent acquisition, stringent quality & compliance, and leveraging cutting-edge technologies. Management's outlook is positive, focusing on strong corporate governance and responsiveness to customer needs for continued growth in favorable market conditions.